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Background
Several studies linked the use of levodopa to an increase in ho-
mocysteine level, which can lead eventually to ischemic heart
disease (IHD) in Parkinson’s disease (PD) patients. There is
a lack of large population studies that have investigated the
cardiovascular safety of levodopa.
Objectives
The main objective of the study is to investigate the one-year
risk of IHD hospitalisation, all-cardiovascular hospital hospital-
isation, and all-cause mortality among users of L-dopa com-
pared with users of Monoamine oxidase B (MAO-B) inhibitors
(as a reference).
Methods
A population-based study evaluated data obtained from the
Secure Anonymised Information Linkage (SAIL) Databank of
residents in Wales, aged 40 years or older, newly treated with
PD medications between 2000 and 2016. The General Practice
(GP) database was used to identify the PD diagnostic codes,
PD medications, and other medications used by PD patients.
Hospital data were used to identify the first hospitalisation
event (IHD and other cardiovascular events). A fully adjusted
propensity score multivariate Cox regression analysis was used
to examine associations between levodopa and the study out-
comes. The index date was set at the date of the first PD
prescription in the newly diagnosed PD patients. Other vari-
ables included gender, comorbidities, social deprivation score
and previous medications history were controlled for.
Findings
There were 5,140 participants on levodopa and 494 on MAO-
B inhibitors. L-dopa was not associated with IHD (p=0.561),
other cardiovascular events (p=0.233), or all-cause mortality
(p=0.334). For IHD, the lack of difference was seen also in
the unadjusted model and in the age-only adjusted model.
Conclusions
This study has shown that L-dopa does not increase the risk
of IHD, cardiovascular risk, or all-cause mortality in the newly
diagnosed PD patient within one year after the therapy initi-
ation. This could contribute to the safety profile of L-dopa
therapy. Future research with a longer follow up period is
warranted.
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